Prospects and challenges for the development of new therapies for Ewing sarcoma

Patrick J. Grohar, Lee J. Helman

Research output: Contribution to journalArticle

Abstract

The Ewing sarcoma family of tumors or Ewing sarcoma (ES) is the second most common malignant bone tumor of childhood. The prognosis for localized Ewing sarcoma has improved through the development of intense multimodal therapy over the past several decades. Unfortunately, patients with recurrent or metastatic disease continue to have a poor prognosis. Therefore, a number of complementary approaches are being developed in both the preclinical and clinical arenas to improve these outcomes. In this review, we will discuss efforts to directly target the biologic drivers of this disease and relate these efforts to the experience with several different agents both in the clinic and under development. We will review the data for compounds that have shown excellent activity in the clinic, such as the camptothecins, and summarize the biological data that supports this activity. In addition, we will review the clinical experience with IGF1 targeted agents, ET-743 and epigenetically targeted therapies, the substantial amount of literature that supports their activity in Ewing sarcoma and the challenges remaining translating these therapies to the clinic. Finally, we will highlight recent work aimed at directly targeting the EWS-FLI1 transcription factor with small molecules in Ewing tumors.

Original languageEnglish (US)
Pages (from-to)216-224
Number of pages9
JournalPharmacology and Therapeutics
Volume137
Issue number2
DOIs
StatePublished - Feb 2013
Externally publishedYes

Fingerprint

Ewing's Sarcoma
trabectedin
Therapeutics
Camptothecin
Ambulatory Care Facilities
Neoplasms
Transcription Factors
Bone and Bones

Keywords

  • Camptothecin
  • Ewing sarcoma
  • Insulin like growth factor (IGF)
  • Mithramycin
  • Poly ADP ribose polymerase (PARP)
  • Trabectedin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Prospects and challenges for the development of new therapies for Ewing sarcoma. / Grohar, Patrick J.; Helman, Lee J.

In: Pharmacology and Therapeutics, Vol. 137, No. 2, 02.2013, p. 216-224.

Research output: Contribution to journalArticle

Grohar, Patrick J. ; Helman, Lee J. / Prospects and challenges for the development of new therapies for Ewing sarcoma. In: Pharmacology and Therapeutics. 2013 ; Vol. 137, No. 2. pp. 216-224.
@article{84b45369fac7471a833ad8e535571eda,
title = "Prospects and challenges for the development of new therapies for Ewing sarcoma",
abstract = "The Ewing sarcoma family of tumors or Ewing sarcoma (ES) is the second most common malignant bone tumor of childhood. The prognosis for localized Ewing sarcoma has improved through the development of intense multimodal therapy over the past several decades. Unfortunately, patients with recurrent or metastatic disease continue to have a poor prognosis. Therefore, a number of complementary approaches are being developed in both the preclinical and clinical arenas to improve these outcomes. In this review, we will discuss efforts to directly target the biologic drivers of this disease and relate these efforts to the experience with several different agents both in the clinic and under development. We will review the data for compounds that have shown excellent activity in the clinic, such as the camptothecins, and summarize the biological data that supports this activity. In addition, we will review the clinical experience with IGF1 targeted agents, ET-743 and epigenetically targeted therapies, the substantial amount of literature that supports their activity in Ewing sarcoma and the challenges remaining translating these therapies to the clinic. Finally, we will highlight recent work aimed at directly targeting the EWS-FLI1 transcription factor with small molecules in Ewing tumors.",
keywords = "Camptothecin, Ewing sarcoma, Insulin like growth factor (IGF), Mithramycin, Poly ADP ribose polymerase (PARP), Trabectedin",
author = "Grohar, {Patrick J.} and Helman, {Lee J.}",
year = "2013",
month = "2",
doi = "10.1016/j.pharmthera.2012.10.004",
language = "English (US)",
volume = "137",
pages = "216--224",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Prospects and challenges for the development of new therapies for Ewing sarcoma

AU - Grohar, Patrick J.

AU - Helman, Lee J.

PY - 2013/2

Y1 - 2013/2

N2 - The Ewing sarcoma family of tumors or Ewing sarcoma (ES) is the second most common malignant bone tumor of childhood. The prognosis for localized Ewing sarcoma has improved through the development of intense multimodal therapy over the past several decades. Unfortunately, patients with recurrent or metastatic disease continue to have a poor prognosis. Therefore, a number of complementary approaches are being developed in both the preclinical and clinical arenas to improve these outcomes. In this review, we will discuss efforts to directly target the biologic drivers of this disease and relate these efforts to the experience with several different agents both in the clinic and under development. We will review the data for compounds that have shown excellent activity in the clinic, such as the camptothecins, and summarize the biological data that supports this activity. In addition, we will review the clinical experience with IGF1 targeted agents, ET-743 and epigenetically targeted therapies, the substantial amount of literature that supports their activity in Ewing sarcoma and the challenges remaining translating these therapies to the clinic. Finally, we will highlight recent work aimed at directly targeting the EWS-FLI1 transcription factor with small molecules in Ewing tumors.

AB - The Ewing sarcoma family of tumors or Ewing sarcoma (ES) is the second most common malignant bone tumor of childhood. The prognosis for localized Ewing sarcoma has improved through the development of intense multimodal therapy over the past several decades. Unfortunately, patients with recurrent or metastatic disease continue to have a poor prognosis. Therefore, a number of complementary approaches are being developed in both the preclinical and clinical arenas to improve these outcomes. In this review, we will discuss efforts to directly target the biologic drivers of this disease and relate these efforts to the experience with several different agents both in the clinic and under development. We will review the data for compounds that have shown excellent activity in the clinic, such as the camptothecins, and summarize the biological data that supports this activity. In addition, we will review the clinical experience with IGF1 targeted agents, ET-743 and epigenetically targeted therapies, the substantial amount of literature that supports their activity in Ewing sarcoma and the challenges remaining translating these therapies to the clinic. Finally, we will highlight recent work aimed at directly targeting the EWS-FLI1 transcription factor with small molecules in Ewing tumors.

KW - Camptothecin

KW - Ewing sarcoma

KW - Insulin like growth factor (IGF)

KW - Mithramycin

KW - Poly ADP ribose polymerase (PARP)

KW - Trabectedin

UR - http://www.scopus.com/inward/record.url?scp=84872802446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872802446&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2012.10.004

DO - 10.1016/j.pharmthera.2012.10.004

M3 - Article

C2 - 23085431

AN - SCOPUS:84872802446

VL - 137

SP - 216

EP - 224

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 2

ER -